Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

BACKGROUND: Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world brigatinib utilization in the US post other ALK-TKIs. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahanzeb, Mohammad, Lin, Huamao M, Wu, Yanyu, Zhang, Pingkuan, Gorritz, Magdaliz, McGuiness, Catherine B, Huang, Wei-Ti, Sun, Kainan, Chen, Chi-Chang, Camidge, D Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438904/
https://www.ncbi.nlm.nih.gov/pubmed/35781589
http://dx.doi.org/10.1093/oncolo/oyac116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438904/
https://www.ncbi.nlm.nih.gov/pubmed/35781589
http://dx.doi.org/10.1093/oncolo/oyac116

Ejemplares similares